

Special Issue

Neutralizing Antibodies against SARS-CoV-2 and HIV

Message from the Guest Editor

This Special Issue of *Vaccines* includes a collection of reviews and research articles that focus on neutralizing antibodies (NAbs) against SARS-CoV-2 and HIV viruses, covering topics such as the cellular and molecular mechanisms of antibody-mediated antiviral activities, analyses of the antibodies' epitopes on viral antigens, structural bases of the antibody-antigen interactions, as well as implications of therapeutic developments. Our Special Issue aims to provide opinions/commentaries, summaries, and in-depth analyses of neutralizing antibodies against SARS-CoV-2 and HIV-1. In this Special Issue, research areas may include but are not limited to:

- Molecular mechanisms of antigen-antibody interactions of neutralizing, as well as certain non-neutralizing, antibodies against SARS-CoV-2 or HIV-1;
- Analyses of antibody epitopes on SARS-CoV-2 S or HIV-1 Env antigens;
- Current progress and limitations of antibody-based therapeutic development;
- Current progress and limitations of Nabs structure-based immunogen design;
- Your proposed topics that you believe would be potentially interesting to our community.

We look forward to receiving your contributions.

Guest Editor

Dr. Zhi Yang

Department of Cell and Molecular Biology, University of California, Berkeley, CA, USA

Deadline for manuscript submissions

closed (1 August 2024)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/151104

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).